Glenmark Pharmaceuticals expands U.S. OTC market presence with Olopatadine Eye Drops

Glenmark secures FDA approval for its OTC Olopatadine Hydrochloride eye drops, expanding its U.S. presence in the $50.7M allergy relief market. Read More